시장보고서 | 연간정보서비스 | 맞춤형시장조사 | 메일링 | 비교리스트
세계의 복합 피부 및 피부 구조 감염증 치료제 시장 보고서(2025년)
Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025
상품코드 : 1682131
리서치사 : The Business Research Company
발행일 : On Demand Report
페이지 정보 : 영문 200 Pages
 라이선스 & 가격 (부가세 별도)
US $ 4,490 ￦ 6,496,000
PDF (Single User License) help
PDF 보고서를 1명만 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 6,490 ￦ 9,390,000
PDF (Site License) help
PDF 보고서를 동일 사업장의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.
US $ 8,490 ￦ 12,284,000
PDF (Enterprise License) help
PDF 보고서를 동일 기업의 모든 분이 이용할 수 있는 라이선스입니다. 인쇄 가능하며 인쇄물의 이용 범위는 PDF 이용 범위와 동일합니다.


ㅁ Add-on 가능: 고객의 요청에 따라 일정한 범위 내에서 Customization이 가능합니다. 자세한 사항은 문의해 주시기 바랍니다.
ㅁ 보고서에 따라 최신 정보로 업데이트하여 보내드립니다. 배송기일은 문의해 주시기 바랍니다.

한글목차

복합 피부 및 피부 구조 감염증 치료제 시장 규모는 향후 수년간 강력한 성장을 이룰 것으로 전망됩니다. 예측 기간의 성장은 의료비 지출 증가, R&D 활동에 대한 투자 증가, 새로운 항생제에 대한 수요 증가, 항생제 내성 감염 발생 증가, 개인 맞춤형 의약품에 대한 수요 증가에 기인할 수 있습니다.

피부질환의 유병률 증가는 향후 몇 년간의 복합 피부 및 피부 구조 감염증 치료제 시장의 성장을 가속할 것으로 예측됩니다. 박테리아의 치료에는 다양한 항생제가 이용되고 있습니다. 따라서 피부 질환의 발생률 증가는 새로운 복합 피부 및 피부 구조 감염증 치료제의 승인으로 이어지고 인식을 높이고 복합 피부 및 피부 구조 감염증의 조기 진단을 촉진합니다. 예를 들어, 2023년 2월 영국의 암 연구 기관인 Cancer Research UK는 영국에서 매년 평균 흑색종 피부암 신규 발생 건수가 2023-2025년 약 20,800건에서 2038-2040년 약 26,500건으로 증가할 것으로 예상한다고 보고했습니다. 흑색종 이환율이 9% 상승하여 2038-2040년에는 인구 10만명당 연간 33건에 달할 것으로 예측되고 있습니다.

의료 지출 증가는 향후 몇 년간의 복합 피부 및 피부 구조 감염증 치료제 시장의 성장을 더욱 촉진할 것으로 예상됩니다. 의료비 지출은 특정 기간 동안 특정 의료 시스템 또는 경제 내에서 의료 서비스, 관련 상품 및 활동에 대한 총 지출을 의미합니다. 의료비 증가는 복합 피부 및 피부 구조 감염증 치료제에 있어서 중요한 요소이며, 의료 서비스에의 액세스를 향상시킬 뿐만 아니라, 복합 피부 및 피부 구조 감염증 치료제의 연구 개발·유통을 지지하고 있습니다. 2022년 3월 미국 연방 정부 기관인 메디케어 & 메디케이드 서비스 센터는 2021-2030년 국민의료비(NHE) 보고서 중 국민의료비는 2021년부터 2030년에 걸쳐 연평균 5.1%의 비율로 증가하여 약 6조 8,000억 달러에 달할 것으로 예측했습니다. 또한, 메디케어 지출은 연율 7.2%, 메디케이드 지출은 동기간에 연율 5.6% 증가할 것으로 예측되고 있습니다.

목차

제1장 주요 요약

제2장 시장 특징

제3장 시장 동향과 전략

제4장 시장 - 금리, 인플레이션, 지정학, 코로나 및 회복이 시장에 미치는 영향을 포함한 거시경제 시나리오

제5장 세계의 성장 분석과 전략 분석 프레임워크

제6장 시장 세분화

제7장 지역별/국가별 분석

제8장 아시아태평양 시장

제9장 중국 시장

제10장 인도 시장

제11장 일본 시장

제12장 호주 시장

제13장 인도네시아 시장

제14장 한국 시장

제15장 서유럽 시장

제16장 영국 시장

제17장 독일 시장

제18장 프랑스 시장

제19장 이탈리아 시장

제20장 스페인 시장

제21장 동유럽 시장

제22장 러시아 시장

제23장 북미 시장

제24장 미국 시장

제25장 캐나다 시장

제26장 남미 시장

제27장 브라질 시장

제28장 중동 시장

제29장 아프리카 시장

제30장 경쟁 구도와 기업 프로파일

제31장 기타 주요 기업 및 혁신 기업

제32장 세계 시장 경쟁 벤치마킹과 대시보드

제33장 주요 인수합병(M&A)

제34장 최근 시장 동향

제35장 시장의 잠재력이 높은 국가, 부문, 전략

제36장 부록

KTH
영문 목차

영문목차

Complicated skin and skin structure infections (cSSSI) medications are a category of drugs designed to address a range of skin and soft tissue infections (SSTIs) affecting not only the skin but also deeper soft tissues like muscles, fascia, and subcutaneous tissues. These infections typically result from bacterial species and require effective management to prevent complications and enhance patient outcomes.

The primary active ingredients found in drugs for complicated skin and skin structure infections include delafloxacin, vancomycin, ceftaroline, fosamil, linezolid, and others. Delafloxacin, for instance, belongs to the fluoroquinolone antibiotic class, and it is employed for the treatment of skin and skin structure infections caused by specific bacteria. These drugs can be administered through various routes, including oral, topical, and parenteral, and they are utilized by a range of end users, such as hospitals, homecare services, specialty clinics, and others.

The complicated skin and skin structure infections drugs market research report is one of a series of new reports from The Business Research Company that provides complicated skin and skin structure infections drugs market statistics, including complicated skin and skin structure infections drugs industry global market size, regional shares, competitors with a complicated skin and skin structure infections drugs market share, detailed complicated skin and skin structure infections drugs market segments, market trends and opportunities and any further data you may need to thrive in the complicated skin and skin structure infections drugs industry. This complicated skin and skin structure infections drugs market research report delivers a complete perspective of everything you need, with an in-depth analysis of the current and future scenario of the industry.

The complicated skin and skin structure infections drugs market size has grown rapidly in recent years. It will grow from $9.51 billion in 2024 to $10.47 billion in 2025 at a compound annual growth rate (CAGR) of 10.1%. The growth in the historic period can be attributed to infectious disease prevalence, increase in hospital-acquired infections, prevalence of complicated skin and skin structure infections, growing demand for effective treatment options, rising disposable incomes.

The complicated skin and skin structure infections drugs market size is expected to see strong growth in the next few years. It will grow to $15.2 billion in 2029 at a compound annual growth rate (CAGR) of 9.8%. The growth in the forecast period can be attributed to increasing healthcare expenditure, increasing investment in r&d activities, rising demand for novel antibiotics, increasing incidence of antibiotic-resistant infections, growing demand for personalized medicine. Major trends in the forecast period include advancements in wound care products, targeted antibiotics, digital health monitoring, natural and alternative remedies, global collaborations.

The increasing prevalence of skin diseases is anticipated to drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Skin diseases are medical conditions impacting the skin's appearance, structure, and function and may involve the skin, hair, nails, and related tissues. A variety of antibiotic drugs are utilized to treat resistant bacteria in cSSSI cases. Therefore, the rise in skin disease incidence can lead to new cSSSI drug approvals, increase awareness, and promote early diagnosis of complicated skin and skin structure infections. For instance, in February 2023, Cancer Research UK, a UK-based cancer research organization, reported that the average number of new melanoma skin cancer cases each year in the UK is projected to increase from around 20,800 cases in 2023-2025 to approximately 26,500 cases in 2038-2040. This marks a projected 9% rise in melanoma incidence rates, reaching 33 cases per 100,000 people annually by 2038-2040. Thus, the growing prevalence of skin disease is fueling the expansion of the cSSSI drugs market.

Rising healthcare expenditure is expected to further drive the growth of the complicated skin and skin structure infections (cSSSI) drugs market in the coming years. Healthcare expenditure refers to the total spending on healthcare services, related goods, and activities within a specific healthcare system or economy over a given period. Higher healthcare costs are a significant factor for complex skin and skin structure infection medications, not only enhancing access to healthcare services but also supporting the research, development, and distribution of cSSSI medications. For instance, in March 2022, the Centers for Medicare & Medicaid Services, a US-based federal agency, projected in the 2021-2030 National Health Expenditure (NHE) report that national health spending would grow at an average annual rate of 5.1% from 2021 to 2030, reaching nearly $6.8 trillion. Additionally, Medicare spending is anticipated to increase at a 7.2% annual rate, while Medicaid spending is projected to grow by 5.6% annually during the same period. Thus, rising healthcare expenditures are bolstering the growth of the cSSSI drugs market.

To maintain their competitive positions in the complicated skin and skin structure infections drugs market, major companies are committed to developing cutting-edge products. As a case in point, in January 2022, Paladin Labs Inc., a Canadian pharmaceutical company and a subsidiary of Endo International PLC, introduced Xydalba (dalbavancin for injection) in the Canadian market. Xydalba is an intravenous treatment designed for both adults and children aged three months and above, addressing acute bacterial skin and skin structure infections (ABSSSI). This second-generation semi-synthetic lipoglycopeptide antibiotic functions by disrupting the formation of bacterial cell walls, effectively eradicating the bacteria. It demonstrates effectiveness against numerous gram-positive bacteria, including the formidable methicillin-resistant Staphylococcus aureus (MRSA). ABSSSI, denoting Acute Bacterial Skin and Skin Structure Infections, forms a specific subset of complicated skin and skin structure infections (cSSSI).

In March 2022, Cumberland Pharmaceuticals, a pharmaceutical firm based in the United States, joined forces with Tabuk Pharmaceuticals Manufacturing Company to create an innovative antibiotic with life-saving potential for the Middle East. This partnership marked the official launch of Cumberland's Vibativ (telavancin) injection in the Middle East. Vibativ stands as an advanced antibiotic developed to address complicated skin and skin structure infections (cSSIs) attributed to susceptible isolates of gram-positive bacteria. The collaboration entails the exclusive authorization for Tabuk to register and promote the product to patients across Saudi Arabia, Jordan, and potentially other nations in the Middle East. Tabuk Pharmaceuticals Manufacturing Company is a pharmaceutical enterprise headquartered in Saudi Arabia, specializing in the provision of pharmaceutical products within the Middle East and North America.

Major companies operating in the complicated skin and skin structure infections drugs market are Pfizer Inc., Johnson & Johnson, F. Hoffmann-La Roche Ltd., AbbVie Inc., Bayer AG, Novartis AG, Merck & Co. Inc., AstraZeneca PLC, Abbott Laboratories, Sanofi SA, GlaxoSmithKline PLC, Eli Lilly and Company, Cipla Inc., Viatris Inc., Teva Pharmaceutical Industries Ltd., Fresenius Kabi, Macleods Pharmaceuticals, Sun Pharmaceutical Industries Limited, Dr Reddy's Laboratories Ltd., Lupin Pharmaceuticals, Zydus Lifesciences Ltd., Glenmark Pharmaceuticals Ltd., Alkem Laboratories Limited, LEO Pharma, Wockhardt, Paratek Pharmaceuticals, Basilea Pharmaceutica AG, Melinta Therapeutics Inc., Nabriva Therapeutics AG, MerLion Pharmaceuticals GmbH.

Asia-Pacific was the largest region in the complicated skin and skin structure infections drugs market in 2024. The regions covered in complicated skin and skin structure infections drugs report are Asia-Pacific, Western Europe, Eastern Europe, North America, South America, Middle East and Africa.

The countries covered in the complicated skin and skin structure infections drugs market report are Australia, Brazil, China, France, Germany, India, Indonesia, Japan, Russia, South Korea, UK, USA, Canada, Italy, Spain.

The complicated skin and skin structure infections drugs market consists of sales of pain medications, immunosuppressive medications, antiseptics and wound dressings. Values in this market are 'factory gate' values, that is, the value of goods sold by the manufacturers or creators of the goods, whether to other entities (including downstream manufacturers, wholesalers, distributors and retailers) or directly to end customers.

The market value is defined as the revenues that enterprises gain from the sale of goods and/or services within the specified market and geography through sales, grants, or donations in terms of the currency (in USD, unless otherwise specified).

The revenues for a specified geography are consumption values that are revenues generated by organizations in the specified geography within the market, irrespective of where they are produced. It does not include revenues from resales along the supply chain, either further along the supply chain or as part of other products.

Complicated Skin And Skin Structure Infections Drugs Global Market Report 2025 from The Business Research Company provides strategists, marketers and senior management with the critical information they need to assess the market.

This report focuses on complicated skin and skin structure infections drugs market which is experiencing strong growth. The report gives a guide to the trends which will be shaping the market over the next ten years and beyond.

Reasons to Purchase

Where is the largest and fastest growing market for complicated skin and skin structure infections drugs ? How does the market relate to the overall economy, demography and other similar markets? What forces will shape the market going forward? The complicated skin and skin structure infections drugs market global report from the Business Research Company answers all these questions and many more.

The report covers market characteristics, size and growth, segmentation, regional and country breakdowns, competitive landscape, market shares, trends and strategies for this market. It traces the market's historic and forecast market growth by geography.

The forecasts are made after considering the major factors currently impacting the market. These include the Russia-Ukraine war, rising inflation, higher interest rates, and the legacy of the COVID-19 pandemic.

Scope

Table of Contents

1. Executive Summary

2. Complicated Skin And Skin Structure Infections Drugs Market Characteristics

3. Complicated Skin And Skin Structure Infections Drugs Market Trends And Strategies

4. Complicated Skin And Skin Structure Infections Drugs Market - Macro Economic Scenario Including The Impact Of Interest Rates, Inflation, Geopolitics, Covid And Recovery On The Market

5. Global Complicated Skin And Skin Structure Infections Drugs Growth Analysis And Strategic Analysis Framework

6. Complicated Skin And Skin Structure Infections Drugs Market Segmentation

7. Complicated Skin And Skin Structure Infections Drugs Market Regional And Country Analysis

8. Asia-Pacific Complicated Skin And Skin Structure Infections Drugs Market

9. China Complicated Skin And Skin Structure Infections Drugs Market

10. India Complicated Skin And Skin Structure Infections Drugs Market

11. Japan Complicated Skin And Skin Structure Infections Drugs Market

12. Australia Complicated Skin And Skin Structure Infections Drugs Market

13. Indonesia Complicated Skin And Skin Structure Infections Drugs Market

14. South Korea Complicated Skin And Skin Structure Infections Drugs Market

15. Western Europe Complicated Skin And Skin Structure Infections Drugs Market

16. UK Complicated Skin And Skin Structure Infections Drugs Market

17. Germany Complicated Skin And Skin Structure Infections Drugs Market

18. France Complicated Skin And Skin Structure Infections Drugs Market

19. Italy Complicated Skin And Skin Structure Infections Drugs Market

20. Spain Complicated Skin And Skin Structure Infections Drugs Market

21. Eastern Europe Complicated Skin And Skin Structure Infections Drugs Market

22. Russia Complicated Skin And Skin Structure Infections Drugs Market

23. North America Complicated Skin And Skin Structure Infections Drugs Market

24. USA Complicated Skin And Skin Structure Infections Drugs Market

25. Canada Complicated Skin And Skin Structure Infections Drugs Market

26. South America Complicated Skin And Skin Structure Infections Drugs Market

27. Brazil Complicated Skin And Skin Structure Infections Drugs Market

28. Middle East Complicated Skin And Skin Structure Infections Drugs Market

29. Africa Complicated Skin And Skin Structure Infections Drugs Market

30. Complicated Skin And Skin Structure Infections Drugs Market Competitive Landscape And Company Profiles

31. Complicated Skin And Skin Structure Infections Drugs Market Other Major And Innovative Companies

32. Global Complicated Skin And Skin Structure Infections Drugs Market Competitive Benchmarking And Dashboard

33. Key Mergers And Acquisitions In The Complicated Skin And Skin Structure Infections Drugs Market

34. Recent Developments In The Complicated Skin And Skin Structure Infections Drugs Market

35. Complicated Skin And Skin Structure Infections Drugs Market High Potential Countries, Segments and Strategies

36. Appendix

(주)글로벌인포메이션 02-2025-2992 kr-info@giikorea.co.kr
ⓒ Copyright Global Information, Inc. All rights reserved.
PC버전 보기